Orchestra Biomed Reports Q3 2024 Financial Results
Company Announcements

Orchestra Biomed Reports Q3 2024 Financial Results

Orchestra Biomed Holdings, Inc. ( (OBIO) ) has released its Q3 earnings. Here is a breakdown of the information Orchestra Biomed Holdings, Inc. presented to its investors.

Orchestra Biomed Holdings, Inc. is a biomedical innovation company that partners with leading medical device companies to develop and commercialize high-impact healthcare technologies, focusing on treatment solutions for hypertension and artery disease. In its latest quarterly earnings report, Orchestra Biomed reported a net loss of $15.4 million for the third quarter of 2024, an increase from the $13.3 million net loss in the same period of 2023. The company’s revenue totaled $987,000 for the quarter, driven by partnership and product revenues. Despite the losses, the company successfully raised $15 million through an At-The-Market offering, strengthening its financial position. Looking ahead, Orchestra Biomed remains focused on advancing its product candidates towards commercialization, leveraging its strategic partnerships to achieve its development goals.

Related Articles
TheFlyOrchestra BioMed reports Q EPS (41c), consensus (43c)
Catie PowersOBIO Upcoming Earnings Report: What to Expect?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App